Lowell Giffhorn - Spectrascience New CFO, Principal Accounting Officer and Secretary
CFO
Mr. Lowell W. Giffhorn is the Chief Financial Officer, Secretary of the Company. Mr. Giffhorn joined the Company as Chief Financial Officer and Secretary in September 2013. Since 2005, Mr. Giffhorn has served as the Chief Financial Officer and Director of Brendan Technologies, Inc., a developer and marketer of computational analytical software products for the biopharmaceutical industry. Also since 2005, he serves as the Chief Financial Officer of Imagenetix, Inc., a publicly held nutritional supplement company. He was the Chief Financial Officer from 1997 to 2005 and a member of the Board of Directors from 1999 to 2006 of Patriot Scientific Corporationrationration, a publicly held microprocessor and intellectual property firm. From 1992 to 1996 and from 1987 to 1990 he was the CFO of SymTek Systems, Inc. and Vice President of Finance for its successor, SymTek Inc., a supplier of capital equipment to the semiconductor industry. Previous to 1987, he held various financial management positions in industries including defense contracting, hospitality, and public accounting. He obtained a M.B.A. degree from National University in 1975 and a B.S. in Accountancy from the University of Illinois in 1969. He was also a director and chairman of the audit committee of DND Technologies, Inc., a publicly held company, until it was acquired in 2009. Mr. Giffhorn devotes approximately 50 percent of his time to our affairs. since 2013.
| Age | 78 |
| Tenure | 12 years |
| Professional Marks | MBA |
| Address | 11568 Sorrento Valley Road, San Diego, CA, United States, 92121 |
| Phone | 858 847 0200 |
| Web | https://www.spectrascience.com |
Spectrascience New Management Efficiency
The company has return on total asset (ROA) of (0.9247) % which means that it has lost $0.9247 on every $100 spent on assets. This is way below average. Spectrascience New's management efficiency ratios could be used to measure how well Spectrascience New manages its routine affairs as well as how well it operates its assets and liabilities. At present, Spectrascience New's Return On Equity is projected to slightly decrease based on the last few years of reporting. At present, Spectrascience New's Total Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 5.10, whereas Other Assets are forecasted to decline to about 88.4 K.Management Performance
| Return On Asset | -0.92 |
Spectrascience New Leadership Team
Elected by the shareholders, the Spectrascience New's board of directors comprises two types of representatives: Spectrascience New inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spectrascience. The board's role is to monitor Spectrascience New's management team and ensure that shareholders' interests are well served. Spectrascience New's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spectrascience New's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lowell Giffhorn, CFO, Principal Accounting Officer and Secretary | ||
| Michael Oliver, CEO and President COO and Director |
Spectrascience Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spectrascience New a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.92 | ||||
| Current Valuation | 492.38 K | ||||
| Shares Outstanding | 4.92 B | ||||
| Price To Earning | (0.04) X | ||||
| Price To Sales | 73.07 X | ||||
| Revenue | 5.15 K | ||||
| Gross Profit | (196.44 K) | ||||
| EBITDA | (1.99 M) | ||||
| Net Income | (4.47 M) | ||||
| Cash And Equivalents | 27.88 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spectrascience New. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Spectrascience Stock refer to our How to Trade Spectrascience Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spectrascience New. If investors know Spectrascience will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spectrascience New listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Spectrascience New is measured differently than its book value, which is the value of Spectrascience that is recorded on the company's balance sheet. Investors also form their own opinion of Spectrascience New's value that differs from its market value or its book value, called intrinsic value, which is Spectrascience New's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spectrascience New's market value can be influenced by many factors that don't directly affect Spectrascience New's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spectrascience New's value and its price as these two are different measures arrived at by different means. Investors typically determine if Spectrascience New is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spectrascience New's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.